Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.
A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.
The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market.
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of
Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers.
Phase III results with lerodalcibep are in the same ballpark as heavy-hitting established PCSK9 inhibiting drugs.
Putting aside access issues for Leqvio, Novartis has presented data showing that the small interfering RNA directed PCSK9 twice-a-year injection provides consistent low-density lipoprotein cholesterol reduction over six years and more.
The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.
The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.